Tag Archives: Motley Fool

Marathon’s defense of pricey orphan drug getting spotlight in Congress; running a marathon is far easier, and a lot cheaper

Steve’s Take: Marathon Pharmaceuticals LLC (Northbrook IL) caught my attention last month at the inception of an outcry when the company first announced the $89,000 price tag for its newly… Read more »

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?

The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »

Federal judge blocks $54-billion Anthem, Cigna merger; judiciary giving notice who’s boss in court

The News: A federal judge last week (February 6, 2017) blocked health insurer Anthem Inc. (Indianapolis IN) from acquiring rival Cigna Corp. (Bloomfield CT), the second court ruling in recent… Read more »

Gilead’s slog downward accelerates; CEO’s growth reassurances need action–now

The News: Gilead Sciences Inc. (Foster City CA) on Tuesday (February 7, 2017) said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to… Read more »

Walgreens cuts offer for Rite Aid, casting doubt on merger; analysts say deal still alive

The News: Walgreens Boots Alliance (Deerfield IL) on Monday (January 30, 2017) entered into a new agreement with Rite Aid (Camp Hill PA) to buy the drugstore chain for at least $2 less per share… Read more »

J&J finally captures Actelion for $30 billion; deal looks good for both unless “what ifs” bite pharma giant’s shareholders

The News: It took months but Swiss biotech Actelion Ltd. (Allschwil) said on Thursday (January 26, 2017) it had agreed to be purchased by Johnson & Johnson (New Brunswick NJ) in a… Read more »

Alexion Suddenly Ousts CEO, CFO; what’s really going on?

Alexion Pharmaceuticals Inc. (New Haven CT), maker of one of the world’s most expensive medicines, announced on Monday (December 12, 2106) its CEO and CFO were departing amid an internal… Read more »

Pfizer misses 3Q views but gets nod for Prevnar from China; Mao would scowl, but not Xi

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a thumbs up for top-selling… Read more »